Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell
transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is
around 10%. Therefore, it is necessary to explore treatment strategy that can support
chemotherapy or improve immunity. Umbilical cord blood is rich in hematopoietic stem cells
and immune cells. However,Cord blood transplantation for adults is still being explored. The
application of cord blood in supportive treatment can be actively explored. Cord blood has
low immunogenicity and is unlikely to cause Graft versus host disease (GVHD), and the
infusion is relatively safe. The Department of Hematology of Shanghai Ruijin Hospital has
conducted a related phase II clinical study, and found that cord blood transfusion reduced
the chance of infection and increased the 2-year survival. Our subject is a prospective
single-arm clinical study. It is planned to recruit 20 elderly AML patients to explore
whether the application of cord blood infusion can further improve the prognosis of patients
during their consolidation chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University